DRUG UTILIZATION DATA IN RISK BENEFIT ANALYSES OF DRUGS - SESSION-III - DISCUSSION

被引：0
|
作者：
CROUT, R
WIHOLM, BE
SHAPIRO, S
INMAN, WHW
VESSEY, M
HALL, RC
JONES, JK
CROOKS, J
WADE, OL
SKEGG, D
DUKES
FRIEBEL
HJORT, P
SJOQVIST, F
HEKSTER
BIRKETT
机构：
来源：
ACTA MEDICA SCANDINAVICA | 1984年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：149 / 152
页数：4
相关论文
共 50 条
  • [41] Therapeutic Drug Monitoring of Antidementia Drugs: A Valid Tool for Successful Individual Benefit/Risk Evaluation
    Koeber, R.
    Kluenemann, H. H.
    Melchner, D.
    Haen, E.
    DRUG SAFETY, 2008, 31 (10) : 902 - 903
  • [42] Impact of Pharmacy Benefit Design on Prescription Drug Utilization: A Fixed Effects Analysis of Plan Sponsor Data
    Roebuck, M. Christopher
    Liberman, Joshua N.
    HEALTH SERVICES RESEARCH, 2009, 44 (03) : 988 - 1009
  • [43] Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    Eichler, Hans-Georg
    Pignatti, Francesco
    Flamion, Bruno
    Leufkens, Hubert
    Breckenridge, Alasdair
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (10) : 818 - 826
  • [44] Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    Hans-Georg Eichler
    Francesco Pignatti
    Bruno Flamion
    Hubert Leufkens
    Alasdair Breckenridge
    Nature Reviews Drug Discovery, 2008, 7 : 818 - 826
  • [45] Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
    Tie, Jeanne
    Cohen, Joshua D.
    Wang, Yuxuan
    Christie, Michael
    Simons, Koen
    Lee, Margaret
    Wong, Rachel
    Kosmider, Suzanne
    Ananda, Sumitra
    McKendrick, Joseph
    Lee, Belinda
    Cho, Jin Hee
    Faragher, Ian
    Jones, Ian T.
    Ptak, Janine
    Schaeffer, Mary J.
    Silliman, Natalie
    Dobbyn, Lisa
    Li, Lu
    Tomasetti, Cristian
    Papadopoulos, Nicholas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    JAMA ONCOLOGY, 2019, 5 (12) : 1710 - 1717
  • [46] SYMPOSIUM ON CHEMICALLY CONTAMINATED AQUATIC FOOD RESOURCES AND HUMAN CANCER RISK - SEPTEMBER 29 AND 30, 1988 RESEARCH-TRIANGLE PARK, NC - CONCLUDING REMARKS ON SESSION-III - COMMENTARY
    WEISBURGER, JH
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1991, 90 : 147 - 147
  • [47] Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs
    Kontoghiorghes, George J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [48] Key Changes in Benefit-Risk Assessment Guidelines and Implications for Data Analysis in Drug Development
    Hammad, Tarek A.
    Pinto, Cathy Anne
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (04): : 366 - 372
  • [49] Letter to the Editor: Discussion on the suicide risk of CCB drugs: based on real-world drug safety surveillance
    Luo, Dongqiang
    Wu, Jiayu
    Liu, Bingshuo
    PSYCHOLOGICAL MEDICINE, 2024, 54 (16) : 4930 - 4932
  • [50] PROSPECTIVE BENEFIT-RISK MONITORING OF NEW DRUGS FOR RAPID ASSESSMENT OF NET FAVORABILITY IN ELECTRONIC HEALTHCARE DATA
    Gagne, J. J.
    Bykov, K.
    Najafzadeh, M.
    Choudhry, N. K.
    Martin, D. P.
    Kahler, K.
    Rogers, J. R.
    Schneeweiss, S.
    VALUE IN HEALTH, 2015, 18 (03) : A11 - A11
12345